LOS ANGELES, Oct. 21 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on MediciNova Inc. (Nasdaq: MNOV) and maintains its $8.50 price. "MediciNova recently announced positive preliminary data on MN-221. MN-221, if approved, will garner a sizable percentage of the asthma market potentially resulting in hundreds of millions of dollars in sales for MediciNova. Medicinova's other clinical candidate, MN-166, is intended for the treatment of multiple sclerosis (MS) and MS is a multi-billion dollar market. As the Company announces additional positive data the value of Medicinova will increase," said Ross Silver, Director of Research for Vista Partners. For more information and to download the FREE report, please visit the Vista Partners website at http://www.vistap.com and click on the download research icon.
About Vista Partners:
Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.
About MediciNova, Inc.:
MediciNova, Inc. is a publicly-traded biopharmaceutical company focused
on acquiring and developing novel, small-molecule therapeutics for the
treatment of diseases with unmet medical need with a specific focus on the
U.S. market. Through strategic alliances primarily with Japanese
pharmaceutical companies, MediciNova holds rights to a diversified
portfolio of clinical and preclinical product candidates, each of which
MediciNova believes has a well-characterized and differentiated therapeutic
profile, attractive commercial potential and patent assets having claims of
commercially adequate scope. MediciNova's pipeline includes six
clinical-stage compounds for the treatment of status asthmaticus, multiple
sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized
Anxiety Disorder, preterm labor and urinary incontinence and two
preclinical-stage compounds for the treatment of thrombotic disorders.
MediciNova's current strategy is to focus its resources on the development
and commercialization of two prioritized assets in its development
pipeline: MN-221 for the treatment of status asthmaticus, an acute, severe
asthma attack, and MN-166 for the treatment of multiple sclerosis.
MediciNova will seek to monetize its other product candidates at key value
inflection points. For more information on MediciNova, Inc., please visit
Vista Partners LLC
|SOURCE Vista Partners|
Copyright©2008 PR Newswire.
All rights reserved